4%) of 17 patients who experienced nitroimidazole treatment failure were cured after treatment with nitazoxanide and paromomycin
52 OLWE (c) 203 [+ or -] 57 196 [+ or -] 11 0,71 Drug Paromomycin
Neomycin confers resistance toward paromomycin
Treatment of ALA (a) Drug Adult dosage Side effects Metronidazole 750 mg tid X 7-10 days ~10%: headache, dizziness, nausea, anorexia, vomiting <1%: ataxia, seizures, paraesthesias, peripheral neuropathy, disulfiram-like reaction with alcohol, metallic taste, vaginal candidiasis -or- Tinidazole 2 g/d divided tid X 3 days Similar to metronidazole, but typically better tolerated -followed by- Iodoquinol 650 mg tid X 20 days Optic neuritis with long-term use; generally well tolerated -or- Paromomycin
25-35 mg/kg/d divided tid 1-10%: diarrhea, X 7 days nausea, vomiting, abdominal cramps, heartburn <1%: headache, vertigo, eosinophilia, rash, pruritus, ototoxicity -or- Diloxanide furoate 500 mg tid X 10 days Flatulence, nausea, vomiting, pruritus, urticaria (a) ALA, amebic liver abscess.
We describe how to construct such a gun, its basic principles of operation and provide a summary of our success using both tungsten and gold particles to transform Paramecium with linear and circular pP XV-NEO, a plasmid that can confer paromomycin
resistance to Paramecium.
Among the many agents that have been used are pentavalent antimonials (which cause some systemic toxicity and are used to treat the mucocutaneous form), pentamidine, amphotericin B (which is used primarily for visceral leishmaniasis), paromomycin
(used for the visceral and cutaneous forms), cytokines such as interferon gamma (used for some mucocutaneous forms, including those caused by Leishmania braziliensis strains), oral antifungals such as ketoconazole, fluconazole, and itraconazole (which are well tolerated), and hipoxanthine (which inhibits purine anabolism and slows Leishmania proliferation).
PATH's Drug Development program announced today the successful completion of a phase 3(b) clinical trial in Bangladesh for the antibiotic Paromomycin
Intramuscular Injection (PMIM), developed to treat visceral leishmaniasis (VL or kala-azar).
Comparison of the effectiveness of two topical paromomycin
treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
Since its inception, DNDi has delivered six new treatments for neglected patients: two fixed-dose antimalarials (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy (NECT) for late-stage sleeping sickness, sodium stibogluconate and paromomycin
(SSG&PM) combination therapy for visceral leishmaniasis in Africa, a set of combination therapies for visceral leishmaniasis in Asia, and a paediatric dosage form of benznidazole for Chagas disease.
Treatment with anthelminthics (praziquantel for most; bithionol, paromomycin
, or sodium amidotrizoate and meglumine amidotrizoate [Gastrografin; Bayer Schering Pharma AG, Berlin, Germany] for a few with older cases) showed that 69 (95%) of 73 patients were infected with 1 tapeworm, 2 were infected with 2 tapeworms, and 2 were infected with 3 tapeworms.
It was decided to treat patients with paromomycin
and amphotericin B.
These drugs include neomycin sulfate, paromomycin
, natamycin, ketoconazole, ciclopirox olamine,  pentamidine isethionate, propamidine isethionate, stilbamidine isethionate,  amphotericin B, sulfadiazine, sulfisoxazole, sulfamethoxazole, polymyxin B and E,  and clotrimazole.